This study is investigating a drug to treat Plaque Psoriasis and other related conditions also associated with abnormal inflammatory responses. The study drug is a monoclonal antibody (mAb) meaning that it can specifically inhibit the protein, IL-36, by binding to IL-36 receptor.
Plaque Psoriasis is when the body has an abnormal immune response to external stimuli that causes a potentially life threatening inflammatory state which results in itchy rashes and dry skin. One protein which is key to triggering this inflammatory cascade is the protein IL-36. Animal studies have shown that by inhibiting IL-36, the detrimental inflammatory cascade is suppressed.
If you would like more information about this study or are interested in participating, please call us on 1800 243 733 or click on the button below to register your interest.